Extensively drug-resistant tuberculosis: epidemiology and management

Alberto Matteelli,1 Alberto Roggi,1 Anna CC Carvalho21Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-Infection, University of Brescia, Brescia, Italy; 2Laboratory of Innovations in Therapies, Education and Bioproducts (LITEB), Oswaldo Cruz Institute (IOC), Oswa...

Full description

Bibliographic Details
Main Authors: Matteelli A, Roggi A, Carvalho ACC
Format: Article
Language:English
Published: Dove Medical Press 2014-04-01
Series:Clinical Epidemiology
Online Access:http://www.dovepress.com/extensively-drug-resistant-tuberculosis-epidemiology-and-management-a16299
_version_ 1811321933008994304
author Matteelli A
Roggi A
Carvalho ACC
author_facet Matteelli A
Roggi A
Carvalho ACC
author_sort Matteelli A
collection DOAJ
description Alberto Matteelli,1 Alberto Roggi,1 Anna CC Carvalho21Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-Infection, University of Brescia, Brescia, Italy; 2Laboratory of Innovations in Therapies, Education and Bioproducts (LITEB), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, BrazilAbstract: The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.Keywords: XDR-TB, epidemiology, control, diagnosis, treatment
first_indexed 2024-04-13T13:26:19Z
format Article
id doaj.art-8ebc9036a8c44b9a9c736368734384b0
institution Directory Open Access Journal
issn 1179-1349
language English
last_indexed 2024-04-13T13:26:19Z
publishDate 2014-04-01
publisher Dove Medical Press
record_format Article
series Clinical Epidemiology
spelling doaj.art-8ebc9036a8c44b9a9c736368734384b02022-12-22T02:45:09ZengDove Medical PressClinical Epidemiology1179-13492014-04-012014default11111816299Extensively drug-resistant tuberculosis: epidemiology and managementMatteelli ARoggi ACarvalho ACCAlberto Matteelli,1 Alberto Roggi,1 Anna CC Carvalho21Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-Infection, University of Brescia, Brescia, Italy; 2Laboratory of Innovations in Therapies, Education and Bioproducts (LITEB), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, BrazilAbstract: The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.Keywords: XDR-TB, epidemiology, control, diagnosis, treatmenthttp://www.dovepress.com/extensively-drug-resistant-tuberculosis-epidemiology-and-management-a16299
spellingShingle Matteelli A
Roggi A
Carvalho ACC
Extensively drug-resistant tuberculosis: epidemiology and management
Clinical Epidemiology
title Extensively drug-resistant tuberculosis: epidemiology and management
title_full Extensively drug-resistant tuberculosis: epidemiology and management
title_fullStr Extensively drug-resistant tuberculosis: epidemiology and management
title_full_unstemmed Extensively drug-resistant tuberculosis: epidemiology and management
title_short Extensively drug-resistant tuberculosis: epidemiology and management
title_sort extensively drug resistant tuberculosis epidemiology and management
url http://www.dovepress.com/extensively-drug-resistant-tuberculosis-epidemiology-and-management-a16299
work_keys_str_mv AT matteellia extensivelydrugresistanttuberculosisepidemiologyandmanagement
AT roggia extensivelydrugresistanttuberculosisepidemiologyandmanagement
AT carvalhoacc extensivelydrugresistanttuberculosisepidemiologyandmanagement